Antagonistic effects of smoking and maternal glycemia on fetal growth: a retrospective study among 13,958 pregnant French women.

IF 3.9 2区 医学 Q2 ENDOCRINOLOGY & METABOLISM
Frontiers in Endocrinology Pub Date : 2025-03-14 eCollection Date: 2025-01-01 DOI:10.3389/fendo.2025.1527358
Emmanuel Cosson, Lionel Carbillon, Sopio Tatulashvili, Hélène Bihan, Eric Vicaut, Ines Barka, Sara Pinto, Imen Rezgani, Mohamed Zerguine, Jean-Jacques Portal, Marion Fermaut, Jardena J Puder, Amélie Benbara
{"title":"Antagonistic effects of smoking and maternal glycemia on fetal growth: a retrospective study among 13,958 pregnant French women.","authors":"Emmanuel Cosson, Lionel Carbillon, Sopio Tatulashvili, Hélène Bihan, Eric Vicaut, Ines Barka, Sara Pinto, Imen Rezgani, Mohamed Zerguine, Jean-Jacques Portal, Marion Fermaut, Jardena J Puder, Amélie Benbara","doi":"10.3389/fendo.2025.1527358","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Smoking and hyperglycemia first diagnosed during pregnancy (H1inP) have opposing effects on fetal growth. The aim of this study was to explore adverse pregnancy outcomes, particularly fetal growth, according to the smoking and H1inP status.</p><p><strong>Methods: </strong>We included 13,958 women from a large French dataset (2012-2018). Using multivariable regression analyses, we retrospectively evaluated the risk of large-for-gestational-age (LGA) babies and other adverse outcomes according to the H1inP and smoking status in four groups: no H1inP/non-smoker (group A: <i>n</i> = 10,454, 88.2%), no H1inP/smoker (group B: <i>n</i> = 819, 5.9%), H1inP/non-smoker (group C: <i>n</i> = 2,570, 18.4%), and H1inP/smoker (group D: <i>n</i> = 115, 0.8%).</p><p><strong>Results: </strong>The rates of LGA were 8.9%, 4.0%, 14.6%, and 8.7% in groups A, B, C, and D, respectively (global ANOVA <i>p</i> < 0.0001, factor H1inP <i>p</i> = 0.0003, factor smoking <i>p</i> = 0.0002, and interaction <i>p</i> = 0.48). After adjustment for potential confounders including age, body mass index, employment, ethnicity, parity, hypertension before pregnancy, gestational weight gain, and alcohol and drug consumption, H1inP was associated with a higher risk [odds ratio (OR) = 1.50, 95% confidence interval (95%CI) = 1.30-1.74] and smoking with a lower risk (OR = 0.35, 95%CI = 0.25-0.50) of LGA. In addition, H1inP was associated with a lower total gestational weight gain and a lower rate of small-for-gestational-age (SGA) babies, but higher rates of hypertensive disorders and more frequent caesarean sections and admissions in the neonatal intensive care unit. Smoking was associated with higher rates of SGA, including severe SGA (<3rd centile), and this despite a higher total gestational weight gain. Smoking increased the risk of hypertensive disorders only in women with H1inP.</p><p><strong>Discussion: </strong>Smoking among women with H1inP could mask the risk of maternal hyperglycemia for LGA babies. This could provide a false sense of security for women with H1inP who smoke, particularly when assessing for LGA alone, but these women still face other risks to their health, such as hypertensive disorders and the health of the fetus.</p>","PeriodicalId":12447,"journal":{"name":"Frontiers in Endocrinology","volume":"16 ","pages":"1527358"},"PeriodicalIF":3.9000,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11949801/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Endocrinology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fendo.2025.1527358","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Smoking and hyperglycemia first diagnosed during pregnancy (H1inP) have opposing effects on fetal growth. The aim of this study was to explore adverse pregnancy outcomes, particularly fetal growth, according to the smoking and H1inP status.

Methods: We included 13,958 women from a large French dataset (2012-2018). Using multivariable regression analyses, we retrospectively evaluated the risk of large-for-gestational-age (LGA) babies and other adverse outcomes according to the H1inP and smoking status in four groups: no H1inP/non-smoker (group A: n = 10,454, 88.2%), no H1inP/smoker (group B: n = 819, 5.9%), H1inP/non-smoker (group C: n = 2,570, 18.4%), and H1inP/smoker (group D: n = 115, 0.8%).

Results: The rates of LGA were 8.9%, 4.0%, 14.6%, and 8.7% in groups A, B, C, and D, respectively (global ANOVA p < 0.0001, factor H1inP p = 0.0003, factor smoking p = 0.0002, and interaction p = 0.48). After adjustment for potential confounders including age, body mass index, employment, ethnicity, parity, hypertension before pregnancy, gestational weight gain, and alcohol and drug consumption, H1inP was associated with a higher risk [odds ratio (OR) = 1.50, 95% confidence interval (95%CI) = 1.30-1.74] and smoking with a lower risk (OR = 0.35, 95%CI = 0.25-0.50) of LGA. In addition, H1inP was associated with a lower total gestational weight gain and a lower rate of small-for-gestational-age (SGA) babies, but higher rates of hypertensive disorders and more frequent caesarean sections and admissions in the neonatal intensive care unit. Smoking was associated with higher rates of SGA, including severe SGA (<3rd centile), and this despite a higher total gestational weight gain. Smoking increased the risk of hypertensive disorders only in women with H1inP.

Discussion: Smoking among women with H1inP could mask the risk of maternal hyperglycemia for LGA babies. This could provide a false sense of security for women with H1inP who smoke, particularly when assessing for LGA alone, but these women still face other risks to their health, such as hypertensive disorders and the health of the fetus.

求助全文
约1分钟内获得全文 求助全文
来源期刊
Frontiers in Endocrinology
Frontiers in Endocrinology Medicine-Endocrinology, Diabetes and Metabolism
CiteScore
5.70
自引率
9.60%
发文量
3023
审稿时长
14 weeks
期刊介绍: Frontiers in Endocrinology is a field journal of the "Frontiers in" journal series. In today’s world, endocrinology is becoming increasingly important as it underlies many of the challenges societies face - from obesity and diabetes to reproduction, population control and aging. Endocrinology covers a broad field from basic molecular and cellular communication through to clinical care and some of the most crucial public health issues. The journal, thus, welcomes outstanding contributions in any domain of endocrinology. Frontiers in Endocrinology publishes articles on the most outstanding discoveries across a wide research spectrum of Endocrinology. The mission of Frontiers in Endocrinology is to bring all relevant Endocrinology areas together on a single platform.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信